(Q44554645)

English

Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control

scientific article published in September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control (English)

1 reference

Europe PubMed Central

4 December 2017

1 reference

based on heuristic

inferred from title

author name string

Michael Grimm

1

1 reference

Europe PubMed Central

4 December 2017

Yan Li

2

1 reference

Europe PubMed Central

4 December 2017

Steven C Brunell

3

1 reference

Europe PubMed Central

4 December 2017

Erich Blase

4

1 reference

Europe PubMed Central

4 December 2017

language of work or name

0 references

publication date

1 September 2013

1 reference

Europe PubMed Central

4 December 2017

Postgraduate Medicine

1 reference

Europe PubMed Central

4 December 2017

125

1 reference

Europe PubMed Central

4 December 2017

5

1 reference

Europe PubMed Central

4 December 2017

101-108

1 reference

Europe PubMed Central

4 December 2017

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Determining predictors of response to exenatide in type 2 diabetes

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2704

21 January 2018

Identifiers

10.3810/PGM.2013.09.2704

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44554645&oldid=2027715744"